This study tests two drugs, DPX-Survivac and pembrolizumab, for treating diffuse large B-cell lymphoma (DLBCL), a type of cancer. Some participants will also get a low-dose of cyclophosphamide (CPA), a chemotherapy drug. DLBCL is a cancer affecting white blood cells. The study is open-label, meaning both doctors and patients know which treatment is given. It's a Phase 2b study, which means it's checking how well the treatment works and its safety.
The study enrolls up to 102 adults who have DLBCL that didn’t get better with other treatments. Participants are divided into two groups. Group 1 gets DPX-Survivac, pembrolizumab, and CPA. Group 2 gets just DPX-Survivac and pembrolizumab.
Participants will get treatments over several cycles, with some needing a tumor biopsy before and during the study. The study requires frequent clinic visits and participants must meet certain health criteria to join. It's important to know that some people won't qualify, like those with certain infections or other health issues.
- Up to 102 participants needed.
- Two treatment options, with or without CPA.
- Regular clinic visits required during the study.